There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Marco Ferreira |
| Institution: | University of Glasgow |
| Department: | Neuro Translation Lab |
| Country: | |
| Proposed Analysis: | The data that sampled as part of WP1 (data mining existing human and experimental data) of the AD project. In the WP, we will integrate data that are available to Oxford and GSK in the public domain. We will use state of the art cross-omics analysis (classical statistic and deep learning) to connect findings across: 1. Studies: UK Biobank, AMPAD, ADNI, IMI studies, FinnGen 2. Omics: genetics ,epigenetics, transcriptomics, proteomics, metabolomics and gut microbiome 3. Tissue: blood CSF, DNA , brain, iPSC AD WP1 can serve as a blueprint to set up the platform for future data analysis and storage for the ongoing studies of AD, PD, and ALS. The ADNII data are relevant for AD analysis may be of interest for cross studies of PD and ALS. The analysis below are to provide a proof-of-principle that we can collect and integrate data as described above. The progranulin pathway, a target of GSK, was select at a proof-of-principle to show: 1) we can combine UK Biobank, AMAD and ADNI data on the server an integrate data with the aim to find biomarkers of early pathology and progression and biomarkers for patients stratification. With the data of ADNI we to conduct a series of multi-omics analysis targeting the GRN pathway. ADNI provides unique data on: 1. ATN biomarkers in brain and blood. 2. Longitudinal metabolomics in CSF and brain and blood. 3. Genetic data including genotyping of common and rare variants. 4. Proteomics data. |
| Additional Investigators |
